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Abstract
Melatonin regulates the reproductive cycle, energy metabolism and may also act as a potential antioxidant indoleamine. The 
present study was undertaken to investigate whether long-term melatonin treatment can induce reproductive alterations and 
if it can protect ovarian tissue against lipid peroxidation during ovulation. Twenty-four adult female Wistar rats, 60 days old 
(± 250-260 g), were randomly divided into two equal groups. The control group received 0.3 mL 0.9% NaCl + 0.04 mL 95% 
ethanol as vehicle, and the melatonin-treated group received vehicle + melatonin (100 µg·100 g body weight-1·day-1) both in-
traperitoneally daily for 60 days. All animals were killed by decapitation during the morning estrus at 4:00 am. Body weight gain 
and body mass index were reduced by melatonin after 10 days of treatment (P < 0.05). Also, a marked loss of appetite was 
observed with a fall in food intake, energy intake (melatonin 51.41 ± 1.28 vs control 57.35 ± 1.34 kcal/day) and glucose levels 
(melatonin 80.3 ± 4.49 vs control 103.5 ± 5.47 mg/dL) towards the end of treatment. Melatonin itself and changes in energy 
balance promoted reductions in ovarian mass (20.2%) and estrous cycle remained extensive (26.7%), arresting at diestrus. 
Regarding the oxidative profile, lipid hydroperoxide levels decreased after melatonin treatment (6.9%) and total antioxidant 
substances were enhanced within the ovaries (23.9%). Additionally, melatonin increased superoxide dismutase (21.3%), cata-
lase (23.6%) and glutathione-reductase (14.8%) activities and the reducing power (10.2% GSH/GSSG ratio). We suggest that 
melatonin alters ovarian mass and estrous cyclicity and protects the ovaries by increasing superoxide dismutase, catalase and 
glutathione-reductase activities.
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The rhythm of melatonin (N-acetyl-5-methoxytryptam-
ine) secretion is important for the synchronization of the 
reproductive response with appropriate environmental 
conditions in photoperiodic animals (1). Melatonin is known 
to modulate some physiological functions such as seasonal 
reproduction, energy metabolism and thermoregulation 
in mammals (2). Experimental studies have indicated the 
action of melatonin in nutrition and feed efficiency affecting 
body mass and adiposity index and both energy intake and 
expenditure, with melatonin preferentially acting by reducing 
fat deposits, thus preventing obesity (3,4). However, these 
controversial effects are not yet fully understood. 
It has been shown that melatonin plays key roles in re-
productive function due to its stimulation of ovarian activity 
and the promotion of estrous cyclicity and gonadal atrophy 
depending on photoperiod length (5). Moreover, melatonin 
also regulates folliculogenesis and ovulation (6) since acute 
suppression of luteinizing hormone levels is notable after 
melatonin treatment (7). Also, it has been emphasized that 
melatonin affects the axis by directly binding to granulosa 
cells in the ovary (8). 
During ovulation, the mechanisms causing follicular 
rupture result in exposure of the ovarian surface to delete-
rious agents such as free radicals (9,10). Thus, repeated 
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ovulation and its complex activities are linked to inflammation, 
reactive oxygen species (ROS) formation, and special cytokine 
expression, and may also be involved in the etiopathogenesis 
of ovarian cancer (10,11). Some reports have described the 
presence of ROS in the female reproductive tract, including 
the ovaries (12). Under normal conditions, ROS appear to be 
directly involved in the reproductive physiological functions such 
as steroidogenesis, oocyte development and fertility (12,13). 
Interestingly, the major sources of ROS, including ·OH, O2- 
and H2O2, are derived from macrophages and neutrophils, 
as they are present in the ovaries during ovulation (14). The 
preovulatory follicle has a powerful antioxidant defense, which 
is depleted by the intense peroxidation. As an example, the 
activity of glutathione peroxidase (GSH-Px) may also maintain 
low levels of hydroperoxides inside the ovarian follicles.
The use of melatonin has been investigated as a therapeu-
tic strategy to improve oocyte quality in patients failing to get 
pregnant in earlier in vitro fertilization (15). In addition, melatonin 
has an important role as a ROS scavenger, acting directly and/
or indirectly as a hormone preventing attack by free radicals 
(16). A previous study showed that elevated melatonin levels 
in preovulatory follicles are able to protect granulosa cells and 
the oocyte from the free radicals induced by ovulation (17). 
Melatonin also positively increases both antioxidant enzyme 
activity and gene expression of superoxide dismutase (SOD), 
catalase and GSH-Px, which are fundamental to detoxify most 
of the ROS produced (18).
Although melatonin treatment has been widely used as an 
effective and useful adjuvant for several therapies, including to 
maintain oocyte quality (15), its adverse time-dependent effects 
are still obscure and require further study. The study of long-
term exposure to melatonin may provide new insights into the 
understanding of the physiological and cellular mechanisms 
underlying metabolic changes, appetite signaling and protec-
tive factors in female reproduction. Additionally, it should be 
remembered that possible changes in nutritional status could 
improve or compromise the reproductive viability. Melatonin 
can contribute to decreasing fat pad storages (4), providing a 
better lifespan, and may reduce lipid oxidation, which would 
be of benefit for reproduction, in addition to having a known 
detoxifying role. However, the role of melatonin in such events 
remains unclear and conflicting results have been observed. 
The present study was undertaken to determine if long-
term melatonin administration is able to induce reproductive 
changes and how melatonin exerts its protective action related 
to lipid oxidation and antioxidant activities in the rat ovary dur-
ing ovulation.
Material and Methods
Animals and experimental design
Twenty-four adult female rats (Rattus norvegicus albinus), 
60 days old (± 250-260 g), were obtained from the Department 
of Anatomy, Bioscience Institute, Botucatu Campus (IBB, 
UNESP). The rats were divided into two groups of 12 animals 
each: control, rats receiving standard chow and tap water ad 
libitum and 0.04 mL 95% ethanol + 0.3 mL 0.9% NaCl (1:7, 
v/v) as vehicle; melatonin-treated group, rats receiving stan-
dard chow and tap water ad libitum and vehicle + melatonin. 
All animals were housed in polypropylene cages (43 cm x 30 
cm x 15 cm) with laboratory-grade pine shavings as bedding 
under conditions of controlled room temperature (23 ± 1°C) 
and lighting (12-h light/12-h dark photoperiod, lights switched 
on at 6:00 am). At 90 days of age, females received melatonin 
daily for 60 consecutive days (Figure 1A and B). After the period 
of melatonin treatment, rats cycling in the morning of estrus 
(period of ovulation) at 4:00 am (or Zeitgeber time 22:00, ZT 
22, corresponding to the environmental circadian time set) and 
monitored by vaginal swabs in a dark room using a red light, 
were anesthetized and killed by decapitation for further analy-
sis. The experimental protocols were approved by the Ethics 
Committee of the Institute of Bioscience, UNESP, Botucatu, 
SP, Brazil (protocol #85/07).
Melatonin administration 
For the animals designated to receive exogenous mela-
tonin treatment, successive doses of melatonin (100 μg/100 
g body weight; M-5250, purchased from Sigma Chemical, 
USA) were dissolved in 0.04 mL 95% ethanol, using 0.3 mL 
0.9% NaCl (1:7, v/v) as vehicle (19). The injections (only 
vehicle or vehicle + melatonin) were administered daily ip 
between 6:30 and 7:00 pm (ZT 13; Figure 1A). 
Food and liquid intake
The diet of the animals was prepared in lots of 5 days, 
always at the same time of day (3:00 pm) using a marked 
Figure 1. A, Protocol for melatonin treatment based on Zeitgeber 
time (ZT) corresponding to the environmental circadian time. B, 
Rats received 100 µg melatonin·100 g body weight-1·day-1, ip, 
for 60 days.
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test tube and an analytical scale (Ohaus Traveler™, Ana-
lytica S.A, Colombia). Liquid and food consumption (caloric 
value of standard chow = 2930 kcal/kg) was determined. 
Total energy intake (kcal/day) and feed efficiency (weight 
gain/consumed calories x 100) were evaluated as metabolic 
parameters. Body weight was also measured. At the end of 
treatment, the reproductive organs (uterine horn, ovaries 
and oviducts) were dissected and weighed. Body weight 
and organ weight were measured using an analytical bal-
ance (OwaLabor, Germany). 
Glycemia measurements
The glycemic index was measured with a blood glucose 
sensor (One Touch Ultra System Kit, Lifescan, Italy) using 
blood samples from the caudal vein of the animals. To avoid 
variation, all samples were assessed in an equal volume 
collected from each animal after 12 h of fasting.
Assessment of estrous cyclicity
During the second part of the experiment, animals ex-
hibiting estrous cycles were monitored by colpocytological 
examination (vaginal smears) (20). Cells detaching from 
the vaginal epithelium were removed with a pipette (Lab 
Mate 0.5-10 µL, UK). The filter tips containing 10 µL 0.9% 
saline were discarded after the vaginal secretion had been 
transferred to clean slides. Colpocytological examination 
time was at 9:00 am. Each slide was analyzed under a Zeiss 
Axiophot II microscope (Carl Zeiss, Germany) at 10X and 
25X magnification and digitally photographed.
Determination of lipid hydroperoxide and antioxidant 
systems
After 60 days of melatonin treatment (100 µg·100 g 
body weight-1·day-1), the ovaries were removed rapidly. 
Each ovary was weighed and tissue samples of 40 mg 
were frozen immediately in liquid nitrogen and stored at 
-80°C. The ovary fragments were homogenized using a 
motor-driven Teflon Potter Elvehjem (Scientific Ltd., Eng-
land) tissue homogenizer in 1.25 mL cold 0.1 M phosphate 
buffer, pH 7.4, containing 1 mM ethylenediaminetetraacetic 
acid (EDTA). The homogenate was centrifuged at 10,000 g 
for 15 min. The supernatant fraction was removed for the 
determination of total proteins, lipids, hydroperoxide, serum 
antioxidant capacity, and total antioxidant substances (test 
Kit Randox Laboratories Ltd., Crumlin, Co., UK).
Lipid hydroperoxide (LHP) was measured by Fe2+ to Fe3+ 
oxidation, using a 100-mL sample and a 900-mL reaction 
mixture containing 250 mM FeSO4, 25 mM H2SO4, 100 mM 
xylenol orange, and 4 mM butyl hydroxytoluene in 90% (v/v) 
methanol. Absorbance was measured at 560 nm (21). Total 
antioxidant substances (TAS) were measured by the inhibition 
of LHP formation and measured at 500 nm (22). Spectropho-
tometric assays were carried out using a spectrophotometer 
with a temperature-controlled cuvette chamber (Ultraspec 
with Swift II software, Pharmacia Biotech, UK). 
The enzymatic antioxidant system, reduced glutathione 
(GSH) and oxidized glutathione (GSSG), was investigated 
using the extracted supernatant (22). GSH-Px activity (E.C. 
1.11.1.9) was then analyzed using glutathione oxidation 
reacted with hydrogen peroxide and cumene hydroper-
oxide. GSH reductase (GSH-Rd) activity was determined 
by monitoring NADPH oxidation at 340 nm. The mixture 
contained 1 mM Tris buffer, pH 8.0, 5 mM EDTA, 33 mM 
GSSG and 2 mM NADPH. SOD activity (E.C. 1.15.1.1) was 
determined with NADH and phenazine methosulfate (PMS) 
and reduction of nitroblue tetrazolium (NBT) by superoxides 
at physiological pH. The complete reaction system consisted 
of 50 mM phosphate buffer, pH 7.4, 0.1 mM EDTA, 50 mM NBT, 
78 mM NADH, and 3.3 mM PMS. Catalase (E.C. 1.11.1.6) 
activity was assayed during the decomposition of H2O2 to H2O 
+ O2. The assays of antioxidant activities were performed at 
25°C using a μQuant microplate spectrophotometer (MQX 
200 with KCjunior software, Bio-Tek Instruments, USA). All 
chemicals were purchased from Sigma. 
Statistical analysis
The Student t-test for independent samples was used. 
Data are reported as means ± SEM and statistical signifi-
cance was set at P < 0.05. The statistical software used 
was Sigma Plot version 11.0 and GraphPad Instat version 
4 for graphic design. 
Results
After 60 days of melatonin treatment, there were sig-
nificant differences in body weight. Melatonin-treated rats 
exhibited a body weight reduction after 10 days of treat-
ment, with a remarkable maintenance of body weight gain 
between days 35-60 (Figure 2). As expected, melatonin 
Figure 2. Effects of melatonin (100 µg·100 g body weight-1·day-1) 
on body weight gain during 60 days of treatment. Data are re-
ported as means ± SEM for 10 animals per group. *P < 0.01 vs 
control group on days 10 to 60 of treatment (Student t-test). 
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treatment also reduced total weight gain and body mass 
index by decreasing fat mass (Table 1). Although overall 
food efficiency and liquid consumption were not affected 
by melatonin, there was a reduction in total and relative 
food consumption, as well as a reduced energy intake and 
glucose levels throughout 60 days of melatonin administra-
tion (Table 1, Figure 3). 
During the second half of the daily melatonin treatment, 
when changes in total energy balance were detected, al-
terations in the reproductive cycles were observed, such 
as estrous irregularities, namely, more extensive cycles in 
melatonin-treated rats than controls, with a high frequency 
of continuous metaestrus and diestrus (Table 2). During 
this period, melatonin had no influence on estrous stage. 
Total ovarian mass was significantly reduced in melatonin-
treated rats; however, the relative ovarian mass remained 
unchanged because of the reduced final body weight of 
the animals (Table 2). 
Table 3 shows that total protein concentration remained 
unchanged in ovarian tissues after melatonin treatment. 
LHP levels increased during spontaneous ovulation and 
decreased when melatonin was given. Moreover, TAS were 
higher in melatonin-treated rats than controls, although 
the LHP/TAS ratio was unchanged because of the high 
LHP formation in control animals (Table 3). With respect to 
antioxidant activities, melatonin increased SOD, GSH-Rd 
and catalase activities in ovarian tissues during ovulation. 
Only GSH-Px activity was unchanged after melatonin treat-
ment. Additionally, the reducing power (GSH/GSSG ratio) 
was higher in melatonin-treated rats than in controls, thus 
Figure 3. Influence of melatonin administration (100 µg·100 g 
body weight-1·day-1) on relative food intake for 60 days of rats 
receiving standard chow. Data are reported as means ± SEM for 
10 animals per group. *P < 0.01 vs control group on days 10 to 
60 of treatment (Student t-test). Day 0: Food consumption before 
the beginning of melatonin administration. 
Table 1. Nutritional parameters of female rats after 60 days of 
melatonin treatment.
Parameters Control 
(N = 12)
Melatonin 
(N = 12)
Body weight gain (g) 36.5 ± 10.6 22.5 ± 11.6*
Body mass index (g/cm2) 0.78 ± 0.05 0.66 ± 0.08*
Total food consumption (g/day) 19.57 ± 0.46 17.55 ± 0.43*
Liquid consumption (mL/day) 12.42 ± 0.23 11.06 ± 0.23
Energy intake (kcal/day) 57.35 ± 1.34 51.41 ± 1.28*
Feed efficiency (g/kcal) 63.0 ± 4.56 61.5 ± 4.76
Blood glucose (mg/dL) 103.5 ± 5.47 80.3 ± 4.49*
Data are reported as means ± SEM. *P < 0.05 vs control group 
(Student t-test).
Table 2. Total and relative ovarian mass and duration of estrous 
cycles in female rats throughout 60 days of melatonin treat-
ment. 
Parameters Control
(N = 12)
Melatonin 
(N = 12)
Ovarian mass (g) 0.094 ± 0.01 0.075 ± 0.02*
Ovarian relative mass 
(g/100 g body weight)
0.035 ± 0.01 0.031 ± 0.01
Estrous cycle duration (days) 5.06 ± 0.20 6.90 ± 0.71*
Estrus (h/cycle) 23.92 ± 0.61 21.60 ± 0.92
Metaestrus (h/cycle) 6.72 ± 0.39 25.92 ± 0.39*
Diestrus (h/cycle) 34.56 ± 1.55 91.14 ± 1.48*
Data are reported as means ± SEM. *P < 0.05 vs control group 
(Student t-test).
Table 3. Oxidative and antioxidant status of rat ovaries after 60 
days of melatonin administration. 
Parameters Control 
(N = 12)
Melatonin 
(N = 12)
Ovary protein (mg/100 mg tissue) 26.25 ± 2.52 35.74 ± 5.95
LHP (nmol/g tissue) 450.7 ± 15.3 419.5 ± 14.2*
TAS (%) 52.50 ± 1.47 65.06 ± 4.03*
LHP/TAS (g/tissue) 8.27 ± 0.59 7.47 ± 0.41 
SOD (nmol/mg protein) 1.48 ± 0.12 1.88 ± 0.05*
GSH-Px (nmol/mg protein) 32.3 ± 1.22 30.6 ± 1.72
GSH-Rd (nmol/mg protein) 1.32 ± 0.01 1.55 ± 0.01*
CAT (nmol/mg protein) 2.85 ± 0.25 3.73 ± 0.16*
GSH/GSSG 10.5 ± 0.7 11.7 ± 0.6*
Data are reported as means ± SEM. LHP = lipid hydroperox-
ide; TAS = total antioxidant substances; SOD = superoxide 
dismutase; GSH-Px = glutathione peroxidase; GSH-Rd = gluta-
thione reductase; CAT = catalase; GSH = reduced glutathione; 
GSSG = oxidized glutathione. *P < 0.05 vs control group (Stu-
dent t-test).
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emphasizing the reduced glutathione formation associ-
ated with increasing GSH-Rd activities during exhaustive 
antioxidant renovation. 
 
Discussion
Appetite regulation and energy sources are fundamental 
for the maintenance of caloric balance and body weight gain. 
Melatonin reduced body weight gain, body mass index, total 
and relative food consumption as well as energy intake and 
glucose levels in the present study. There are several possible 
explanations regarding the action of melatonin as a metabolic 
hormone disruptor. Melatonin seems to be directly related to 
the periodicity of food intake (23). Molecular evidence sug-
gests a stronger interaction between melatonin-induced clock 
genes and cell metabolism, including the control of glucose 
homeostasis and adipogenesis (24-26), thereby reducing 
the lipid content. Moreover, melatonin influences the satiety 
process and reduces blood glucose levels (27,28). Taken 
together, our findings concerning the nutritional balance 
could be attributed to one or more of these factors. Similarly, 
a previous study on the effects of melatonin detected body 
weight reduction in animals (29). It has also been demon-
strated that pinealectomized rats do not show a greater 
body weight and, conversely, when they are exposed to a 
short-day photoperiod, a marked reduction of body weight 
is seen (30). Furthermore, these differences may depend 
on factors such as gender, age, or body composition of the 
animals receiving appropriate treatment. 
In the present study, rats receiving melatonin showed 
a reduction in ovarian weight and, additionally, longer es-
trous cycles, which featured an extended metaestrous and 
diestrous phases. It is known that melatonin can increase 
the diestrous frequencies or estrous phases in rodents (31) 
by modulating GnRH hormones, but the exact mechanisms 
involved are poorly understood. Thus, it seems true that 
nutritional improvements were not effectively responsible 
for maintaining regular cycles. Moreover, rats receiving me-
latonin (200 μg·100 g body weight-1·day-1) and exposed to 
continuous light showed longer estrous periods and reduction 
of ovarian weight (32). It is clear that melatonin does not act 
directly on hypothalamic GnRH neurons and its responsive-
ness does not change with the photoperiod (33). Disturbances 
involving neuroendocrine regulation of reproduction appear 
to be associated with hypogonadotropic hypogonadism (34) 
where expression of Kiss 1 is down-regulated by melatonin 
(35). Thus, our findings could be partially explained if mela-
tonin suppressed GnRH hormones. 
It is noteworthy that spontaneous ovulation is a source 
of ROS generation due to the intensive ovarian activity (36). 
Conversely, there is a body of evidence suggesting that me-
latonin plays key roles as a ROS scavenger (15,37). Under 
a variety of physiological conditions, including ovulation 
or follicular rupture, the proteolytic cascade and vascular 
changes lead to ROS production (38). It seems clear that 
increased levels of NADPH-oxidase generate superoxide 
anion radicals (O2-) and hydrogen peroxide (H2O2), which 
in the presence of Fe3+ produces powerful oxidants such 
as hydroxyl radicals, enhancing lipid peroxidation (39). 
In melatonin-treated rats, LHP levels were reduced and 
TAS concentration was increased, although the LHP/TAS 
ratio was not modified by melatonin. Interestingly, lipid 
hydroperoxide levels were higher during spontaneous 
ovulation and underwent a remarkable reduction after 
the administration of melatonin, which quenched hydroxyl 
radicals within ovarian cells, confirming the protective effect 
of the hormone as a ROS scavenger preserving fatty acid 
integrity against aldehyde formation and finally improving 
the lipid profile (40). Also, another sub-product formed as 
a result of melatonin scavenging hydrogen peroxide, i.e., 
N(1)-acetyl-N(2)-formyl-5-methoxykynuramine, is also a 
potent scavenger.
Melatonin had an important effect on the ovaries, induc-
ing higher SOD, catalase and GSH-Rd activity compared 
to control. It is well known that melatonin has an important 
role in transcriptional mRNA synthesis (i.e., gamma-
glutamyl cysteine synthetase and others) for antioxidant 
enzymes (18), suggesting that melatonin regulation is 
receptor-mediated, thereby most likely implicating the MT1/
MT2 receptors via second messengers such as cAMP, 
phospholipase C or intracellular calcium concentration, 
and thus, it might have improved the antioxidant profile if 
they are activated. The antioxidant defense system is an 
integrated array of enzyme and non-enzyme antioxidants. 
In control rats, higher ovarian LHP levels indicated that 
the oxidation of GSH to GSSG, reducing the GSH/GSSG 
ratio, led to lipoperoxidation and oxidative stress. During 
the reduction of hydrogen peroxide, GSH is oxidized to 
GSSG and GSH-Rd is activated to convert oxidized GSSG 
to reduced GSH. Curiously, besides increasing the GSH/
GSSG ratio, melatonin also enhanced GSH-Rd activity. Our 
findings seem to agree with these mechanisms. 
This study demonstrated that long-term melatonin 
treatment modulates body weight gain, calorie storage and 
food intake. Although melatonin reduced ovarian mass and 
caused estrous cycle disturbances, it was able to protect the 
ovaries against lipid peroxidation by reducing LHP levels 
during ovulation. These protective effects could be due to 
the properties of melatonin both as a ROS scavenger and 
as an agent increasing antioxidant activities. 
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